keyword
https://read.qxmd.com/read/38375710/the-relationship-and-diagnostic-efficacy-of-n-terminal-propeptide-type-iii-collagen-in-pathological-changes-associated-with-non-alcoholic-steatohepatitis
#21
JOURNAL ARTICLE
Y-J Mi, Z Zhang, S-L Jin, H-M Yan, X-M Yang, J Zhao, R-X Liu, Y Wu
OBJECTIVE: This study delves into the role of N-terminal propeptide type III collagen (PIIINP) in the diagnosis and management of liver pathological changes associated with non-alcoholic steatohepatitis (NASH). PATIENTS AND METHODS: We collected baseline information, pathological data, and serum PIIINP levels of 168 patients diagnosed with non-alcoholic fatty liver disease (NAFLD) via ultrasound imaging in our hospital. Based on the non-alcoholic fatty liver disease activity score (NAS), patients with different NAFLD patterns were divided into a Definite NASH group and a Not/borderline group...
February 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38370007/prevalence-of-nonalcoholic-steatohepatitis-and-associated-fibrosis-stages-among-us-adults-using-imaging-based-vs-biomarker-based-noninvasive-tests
#22
JOURNAL ARTICLE
Jesse Fishman, Tom O'Connell, Christina M Parrinello, Jonathan J Woolley, Eric Bercaw, Michael R Charlton
Introduction: Nonalcoholic fatty liver disease (NAFLD) is believed to be the most common chronic liver disease worldwide. Therapies are under development for nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, such that the prevalence of NASH with liver fibrosis, which is likely to require treatment, may be of interest to healthcare decision makers. Noninvasive tests are used in initial screening for NASH, as well as in observational studies of NASH prevalence. However, existing evidence does not address how estimated prevalence varies with different noninvasive tests...
2024: Journal of health economics and outcomes research
https://read.qxmd.com/read/38358517/genomics-of-human-nafld-lack-of-data-reproducibility-and-high-interpatient-variability-in-drug-target-expression-as-major-causes-of-drug-failures
#23
JOURNAL ARTICLE
Shifang Tang, Jürgen Borlak
BACKGROUND AIMS: Non-alcoholic-fatty-liver disease (NAFLD) is a major disease burden and a foremost cause of chronic liver disease. Presently, nearly 300 trials evaluate therapeutic efficacy of >20 drugs. Remarkably, the majority of drugs fail. To better comprehend drug failures, we investigated reproducibility of fatty liver genomic data across 418 liver biopsies and evaluated interpatient variability of 18 drug targets. APPROACH RESULTS: Apart from our own data, we retrieved NAFLD biopsy genomic data sets from public repositories and considered patient demographics...
February 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38348568/vegetarian-diets-and-risk-of-nonalcoholic-fatty-liver-disease-an-observational-study-of-national-health-and-nutrition-examination-survey%C3%A2-2005-2018-using-propensity-score-methods
#24
JOURNAL ARTICLE
Rui Li, Ming Li, Alyce D Fly, Aurelian Bidulescu, Juhua Luo
BACKGROUND: Studies on the association between vegetarian diets and nonalcoholic fatty liver disease (NAFLD) are limited and have inconsistent results. This study aims to explore the association between vegetarian diets and NAFLD and compare the stage of fibrosis between vegetarians and nonvegetarians in a US representative sample. METHODS: Cross-sectional data from 23,130 participants aged ≥20 years were obtained from the National Health and Nutrition Examination Survey, 2005-2018...
February 13, 2024: Journal of Human Nutrition and Dietetics: the Official Journal of the British Dietetic Association
https://read.qxmd.com/read/38347338/diagnosis-of-hepatic-steatosis-and-steatohepatitis-in-people-with-new-onset-type-2-diabetes-a-multidisciplinary-approach
#25
JOURNAL ARTICLE
L Barana, A Nelva, P Scivetti, M Costanzo, C G Fanelli
AIMS: Non-Alcoholic-Fatty-Liver-Disease (NAFLD) is the most common cause of chronic liver disease in Western countries; closely linked to obesity and type 2 diabetes (T2DM), it is an additional cardiovascular risk factor. The aim of this study is to investigate the prevalence of NAFLD at T2DM onset. METHODS: 122 newly diagnosed T2DM patients were enroled; NAFLD was diagnosed using ultrasound and fibrosis risk calculated with an FIB4-score. Intermediate and high-risk patients were referred to a hepatologist and underwent transient elastography (TE)...
February 12, 2024: Endocrine
https://read.qxmd.com/read/38340725/p63-controls-metabolic-activation-of-hepatic-stellate-cells-and-fibrosis-via-an-her2-acc1-pathway
#26
JOURNAL ARTICLE
Marcos F Fondevila, Eva Novoa, Maria J Gonzalez-Rellan, Uxia Fernandez, Violeta Heras, Begoña Porteiro, Tamara Parracho, Valentina Dorta, Cristina Riobello, Natalia da Silva Lima, Samuel Seoane, Maria Garcia-Vence, Maria P Chantada-Vazquez, Susana B Bravo, Ana Senra, Magdalena Leiva, Miguel Marcos, Guadalupe Sabio, Roman Perez-Fernandez, Carlos Dieguez, Vincent Prevot, Markus Schwaninger, Ashwin Woodhoo, Maria L Martinez-Chantar, Robert Schwabe, Francisco J Cubero, Marta Varela-Rey, Javier Crespo, Paula Iruzubieta, Ruben Nogueiras
The p63 protein has pleiotropic functions and, in the liver, participates in the progression of nonalcoholic fatty liver disease (NAFLD). However, its functions in hepatic stellate cells (HSCs) have not yet been explored. TAp63 is induced in HSCs from animal models and patients with liver fibrosis and its levels positively correlate with NAFLD activity score and fibrosis stage. In mice, genetic depletion of TAp63 in HSCs reduces the diet-induced liver fibrosis. In vitro silencing of p63 blunts TGF-β1-induced HSCs activation by reducing mitochondrial respiration and glycolysis, as well as decreasing acetyl CoA carboxylase 1 (ACC1)...
February 5, 2024: Cell reports medicine
https://read.qxmd.com/read/38324483/a-phase-3-randomized-controlled-trial-of-resmetirom-in-nash-with-liver-fibrosis
#27
RANDOMIZED CONTROLLED TRIAL
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, Jörn M Schattenberg, Rohit Loomba, Rebecca Taub, Dominic Labriola, Sam E Moussa, Guy W Neff, Mary E Rinella, Quentin M Anstee, Manal F Abdelmalek, Zobair Younossi, Seth J Baum, Sven Francque, Michael R Charlton, Philip N Newsome, Nicolas Lanthier, Ingolf Schiefke, Alessandra Mangia, Juan M Pericàs, Rashmee Patil, Arun J Sanyal, Mazen Noureddin, Meena B Bansal, Naim Alkhouri, Laurent Castera, Madhavi Rudraraju, Vlad Ratziu
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo...
February 8, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38317531/comparison-of-all-cause-mortality-associated-with-non-alcoholic-fatty-liver-disease-and-metabolic-dysfunction-associated-fatty-liver-disease
#28
JOURNAL ARTICLE
Wei-Chun Cheng, Hua-Fen Chen, Hsiu-Chi Cheng, Chung-Yi Li
OBJECTIVES: The global burden of non-alcoholic fatty liver disease (NAFLD) is rising. An alternative term, metabolic dysfunction-associated fatty liver disease (MAFLD), instead highlights the associated metabolic risks. This cohort study examined patient classifications under NAFLD and MAFLD criteria and their associations with all-cause mortality. METHODS: Participants who attended a paid health checkup (2012-2015) were included. Hepatic steatosis (HS) was diagnosed ultrasonographically...
January 21, 2024: Epidemiology and Health
https://read.qxmd.com/read/38314810/diagnostic-ability-of-simple-noninvasive-blood-tests-to-predict-increased-liver-stiffness-in-people-living-with-hiv-and-steatotic-liver-disease
#29
JOURNAL ARTICLE
Richard K Sterling, Eduardo Vilar-Gomez, Laura A Wilson ScM, Rohit Loomba, Samer Gawrieh, Jennifer Price, Susanna Naggie, Jordan E Lake, Sonya Heath, James Tonascia, Mark Sulkowski, Naga Chalasani
BACKGROUND AND AIMS: Steatotic liver disease is common in people with human immunodeficiency virus (HIV)(PWH). Identifying those with advanced fibrosis (AF, bridging fibrosis or cirrhosis), F3-4, is important. We aimed to examine the performance of FIB-4 and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) in PWH to identify those with AF assessed by liver stiffness measurement (LSM). METHODS: We prospectively collected data on adults participating in two NIH-sponsored HIV NAFLD networks...
February 5, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38311058/a-composite-blood-biomarker-including-akr1b10-and-cytokeratin-18-for-progressive-types-of-nonalcoholic-fatty-liver-disease
#30
JOURNAL ARTICLE
Seung Joon Choi, Sungjin Yoon, Kyoung-Kon Kim, Doojin Kim, Hye Eun Lee, Kwang Gi Kim, Seung Kak Shin, Ie Byung Park, Seong Min Kim, Dae Ho Lee
BACKGROUND: We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic steatohepatitis [NASH] marker) have clinically applicable performance for the diagnosis of NASH, advanced liver fibrosis, and high-risk NASH (NASH+significant fibrosis). METHODS: A total of 116 subjects including healthy control subjects and patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) were analyzed to assess composite blood-based and imaging-based biomarkers either singly or in combination...
February 1, 2024: Diabetes & Metabolism Journal
https://read.qxmd.com/read/38310878/glycemic-control-is-associated-with-histological-findings-of-nonalcoholic-fatty-liver-disease
#31
JOURNAL ARTICLE
Teruki Miyake, Shinya Furukawa, Bunzo Matsuura, Osamu Yoshida, Masumi Miyazaki, Akihito Shiomi, Ayumi Kanamoto, Hironobu Nakaguchi, Yoshiko Nakamura, Yusuke Imai, Mitsuhito Koizumi, Takao Watanabe, Yasunori Yamamoto, Yohei Koizumi, Yoshio Tokumoto, Masashi Hirooka, Teru Kumagi, Eiji Takesita, Yoshio Ikeda, Masanori Abe, Yoichi Hiasa
BACKGROUND: Poor lifestyle habits may worsen nonalcoholic fatty liver disease (NAFLD), with progression to nonalcoholic steatohepatitis (NASH) and cirrhosis. This study investigated the association between glycemic control status and hepatic histological findings to elucidate the effect of glycemic control on NAFLD. METHODS: This observational study included 331 patients diagnosed with NAFLD by liver biopsy. Effects of the glycemic control status on histological findings of NAFLD were evaluated by comparing the following four glycemic status groups defined by the glycosylated hemoglobin (HbA1c) level at the time of NAFLD diagnosis: ≤5...
February 2, 2024: Diabetes & Metabolism Journal
https://read.qxmd.com/read/38308212/dietary-intervention-reverses-molecular-markers-of-hepatocellular-senescence-in-the-gan-diet-induced-obese-and-biopsy-confirmed-mouse-model-of-nash
#32
JOURNAL ARTICLE
Mathias Flensted-Jensen, Denise Oró, Emma A Rørbeck, Chen Zhang, Martin Rønn Madsen, Andreas Nygaard Madsen, Jenny Norlin, Michael Feigh, Steen Larsen, Henrik H Hansen
BACKGROUND: Hepatocellular senescence may be a causal factor in the development and progression of non-alcoholic steatohepatitis (NASH). The most effective currently available treatment for NASH is lifestyle intervention, including dietary modification. This study aimed to evaluate the effects of dietary intervention on hallmarks of NASH and molecular signatures of hepatocellular senescence in the Gubra-Amylin NASH (GAN) diet-induced obese (DIO) and biopsy-confirmed mouse model of NASH...
February 2, 2024: BMC Gastroenterology
https://read.qxmd.com/read/38303507/machine-learning-improves-the-prediction-of-significant-fibrosis-in-asian-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-the-gut-and-obesity-in-asia-go-asia-study
#33
JOURNAL ARTICLE
Nipun Verma, Ajay Duseja, Manu Mehta, Arka De, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ruveena Bhavani Rajaram, Wah-Kheong Chan, Sanjiv Mahadeva, Ming-Hua Zheng, Wen-Yue Liu, Sombat Treeprasertsuk, Thaninee Prasoppokakorn, Satoru Kakizaki, Yosuke Seki, Kazunori Kasama, Phunchai Charatcharoenwitthaya, Phalath Sathirawich, Anand Kulkarni, Hery Djagat Purnomo, Lubna Kamani, Yeong Yeh Lee, Mung Seong Wong, Eunice X X Tan, Dan Yock Young
BACKGROUND: The precise estimation of cases with significant fibrosis (SF) is an unmet goal in non-alcoholic fatty liver disease (NAFLD/MASLD). AIMS: We evaluated the performance of machine learning (ML) and non-patented scores for ruling out SF among NAFLD/MASLD patients. METHODS: Twenty-one ML models were trained (N = 1153), tested (N = 283), and validated (N = 220) on clinical and biochemical parameters of histologically-proven NAFLD/MASLD patients (N = 1656) collected across 14 centres in 8 Asian countries...
February 1, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38293684/long-term-major-adverse-liver-outcomes-in-1-260-patients-with-non-cirrhotic-nafld
#34
JOURNAL ARTICLE
Camilla Akbari, Maja Dodd, Per Stål, Patrik Nasr, Mattias Ekstedt, Stergios Kechagias, Johan Vessby, Fredrik Rorsman, Xiao Zhang, Tongtong Wang, Thomas Jemielita, Gail Fernandes, Samuel S Engel, Hannes Hagström, Ying Shang
BACKGROUND & AIMS: Long-term studies of the prognosis of NAFLD are scarce. Here, we investigated the risk of major adverse liver outcomes (MALO) in a large cohort of patients with NAFLD. METHODS: We conducted a cohort study with data from Swedish university hospitals. Patients (n = 1,260) with NAFLD without cirrhosis were diagnosed through biopsy or radiology, and had fibrosis estimated through vibration-controlled transient elastography, biopsy, or FIB-4 score between 1974 and 2020 and followed up through 2020...
February 2024: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/38291699/noninvasive-scores-are-poorly-predictive-of-histological-fibrosis-in-paediatric-fatty-liver-disease
#35
JOURNAL ARTICLE
Laura Kalveram, Ulrich Baumann, Ruth De Bruyne, Laura Draijer, Wojciech Janczyk, Deirdre Kelly, Bart G Koot, Florence Lacaille, Sander Lefere, Hadar Moran Lev, Judith Lubrecht, Jake P Mann, Antonella Mosca, Sanjay Rajwal, Piotr Socha, Anita Vreugdenhil, Anna Alisi, Christian A Hudert
OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children. Roughly a quarter of paediatric patients with NAFLD develop nonalcoholic steatohepatitis and fibrosis. Here, we evaluated the diagnostic accuracy of previously published noninvasive fibrosis scores to predict liver fibrosis in a large European cohort of paediatric patients with NAFLD. METHODS: The 457 patients with biopsy-proven NAFLD from 10 specialized centers were included...
January 2024: Journal of Pediatric Gastroenterology and Nutrition
https://read.qxmd.com/read/38283271/predicting-fibrosis-progression-in-non-alcoholic-fatty-liver-disease-patients-using-the-fast-score-a-paired-biopsy-study
#36
JOURNAL ARTICLE
Nisanur Sariyar, Haluk Tarik Kani, Cigdem Ataizi Celikel, Yusuf Yilmaz
BACKGROUND AND AIM: This study aimed to investigate the predictive value of various non-invasive scores for identifying the progression of hepatic fibrosis over time in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). MATERIALS AND METHODS: We examined 69 patients with NAFLD who had undergone two liver biopsies at an average interval of 21.3±9.7 months. Progression and regression of fibrosis were defined as an increase or decrease of at least one stage in fibrosis between the initial and follow-up biopsies, respectively...
2024: Hepatol Forum
https://read.qxmd.com/read/38278311/non-contrast-t1%C3%AF-dispersion-versus-gd-eob-dtpa-enhanced-t1mapping-for-the-risk-stratification-of-non-alcoholic-fatty-liver-disease-in-rabbit-models
#37
JOURNAL ARTICLE
Ru Yang, Zhongshan Chen, Jin Pan, Shimin Yang, Fubi Hu
PURPOSE: To investigate the diagnostic efficacy of T1ρ dispersion and Gd-EOB-DTPAenhanced T1mapping in the identification of early liver fibrosis (LF) and non-alcoholic steatohepatitis (NASH) in a non-alcoholic fatty liver disease (NAFLD) rabbit model induced by a high-fat diet using histopathological findings as the standard reference. METHODS: A total of sixty rabbits were randomly allocated into the standard control group (n = 12) and the NAFLD model groups (8 rabbits per group) corresponding to different high-fat high cholesterol diet feeding weeks...
January 24, 2024: Magnetic Resonance Imaging
https://read.qxmd.com/read/38274398/the-use-of-noninvasive-velacur%C3%A2-for-discriminating-between-volunteers-and-patients-with-chronic-liver-disease-a-feasibility-study
#38
JOURNAL ARTICLE
Michael P Curry, Edward Tam, Caitlin Schneider, Noha Abdelgelil, Tarek Hassanien, Nezam H Afdhal
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease is the leading cause of chronic liver disease globally and can progress to cirrhosis, liver failure, and liver cancer. Current AASLD, AGA, and ADA guidelines recommend assessment for liver fibrosis in all patients with NAFLD. Serum biomarkers for fibrosis, while widely available, have notable limitations. Imaging-based noninvasive testing for liver fibrosis/cirrhosis is more accurate and is becoming more widespread. METHODS: We evaluated the feasibility of a novel shear wave absolute vibroelastography (S-WAVE) modality called Velacur® for assessing liver stiffness measurement (LSM) for fibrosis and attenuation coefficient estimation (ACE) in differentiating patients with chronic liver disease from normal healthy controls...
2024: International Journal of Hepatology
https://read.qxmd.com/read/38272486/metabolic-dysfunction-associated-fatty-liver-disease-and-nonalcoholic-fatty-liver-disease-from-clinical-to-pathological-characteristics-a-multi-center-cross-sectional-study-in-real-world
#39
JOURNAL ARTICLE
Yan Li, Changyong Dai, Yuhua Ruan, Haiqing Yang, Huang Zeng, Rui Huang, Jialu Wang, Mingjia Dai, Jungui Hao, Liping Wang, Jie Li, Xuebing Yan, Zhonghua Lu, Fang Ji
BACKGROUND: The evaluation of patients with fatty liver as defined by metabolic dysfunction-associated fatty liver disease (MAFLD) in the real world remains poorly researched. This study aimed to analyse the clinical and histological features of patients with MAFLD and nonalcoholic fatty liver disease (NAFLD) and to characterize each metabolic subgroup of MAFLD. METHODS: A total of 2563 patients with fatty liver confirmed by ultrasonography and/or magnetic resonance tomography and/or liver biopsy-proven from three hospitals in China were included in the study...
January 25, 2024: Postgraduate Medical Journal
https://read.qxmd.com/read/38263684/prognosis-of-biopsy-confirmed-masld-a-sub-analysis-of-the-clione-study
#40
JOURNAL ARTICLE
Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue
BACKGROUND/AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis in patients with biopsy-confirmed MASLD using data from a multicenter study. METHODS: This is a sub-analysis of the CLIONE (Clinical Outcome Nonalcoholic Fatty Liver Disease) study, included 1,398 patients with NAFLD. Liver biopsy specimens were pathologically diagnosed, and histologically scored using the NASH Clinical Research Network system...
January 24, 2024: Clinical and Molecular Hepatology
keyword
keyword
112750
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.